Freeport-McMoRan stock tumbles after Trump imposes copper tariffs
SAN FRANCISCO — Finn Patrick John, the President and Chief Operating Officer of Twist Bioscience Corp (NASDAQ:TWST), recently sold shares of the company’s common stock. The sale, disclosed in a filing with the Securities and Exchange Commission, involved 206 shares sold at a price of $38.733 per share, totaling $7,978. The transaction comes as the company, currently valued at $2.2 billion, maintains a strong balance sheet with more cash than debt.
This transaction was conducted to cover tax withholding obligations associated with the vesting of Restricted Stock Units. As noted in the filing, these sales were not discretionary trades by Finn but were mandated by the company’s equity incentive plans. The stock has shown significant volatility, with a beta of 2.34 and a 52-week trading range of $27.41 to $60.90.
Following this transaction, Finn holds 267,518 shares of Twist Bioscience directly. The company, based in South San Francisco, specializes in the production of synthetic DNA for various applications in the life sciences sector. With a healthy current ratio of 4.96 and revenue growth of 26% in the last twelve months, InvestingPro analysis suggests the company shows good financial health despite current unprofitability. Investors can access detailed valuation metrics and 7 additional ProTips through InvestingPro’s comprehensive research report.
In other recent news, Twist Bioscience Corporation reported financial results for the first quarter of fiscal year 2025 that exceeded consensus predictions and company guidance. The company revised its full-year fiscal 2025 guidance upward, projecting total revenue growth of 19-21% year-over-year. Gross margins are expected to be around 49% for the full year, with an improvement anticipated in the fourth quarter. In addition, Twist Bioscience held its Annual Meeting of Stockholders, resulting in the approval of an increase in authorized common stock by an additional 100 million shares and amendments to the company’s equity incentive plan. These changes aim to provide more flexibility in compensating and incentivizing employees.
Furthermore, analysts have shown optimism regarding Twist Bioscience’s prospects. Scotiabank (TSX:BNS) raised the company’s price target to $62, maintaining a Sector Outperform rating, while Barclays (LON:BARC) increased its target to $58 and reiterated an Overweight rating. The analysts highlighted the company’s momentum in its Express portfolio and Next-Generation Sequencing tools. Barclays also noted the potential for significant technological milestones in DNA storage and the company’s minimal cash burn. These developments signal a positive outlook for Twist Bioscience as it continues to focus on profitability and innovation.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.